Tvardi Therapeutics has dosed the first patients in each arm of its Phase II REVERT Liver Cancer trial of TTI-101 to treat locally advanced or metastatic, and unresectable hepatocellular carcinoma (HCC).
The ongoing study is assessing the clinical activity and safety of TTI-101 alone and along with standard of care therapy in HCC patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is currently enrolling patients from top cancer research institutes in the US.
TTI-101 as a monotherapy is evaluated in patients who were previously treated with up to three lines of systemic therapy.
In combination therapy, TTI-101 is assessed along with pembrolizumab (Keytruda) in patients previously treated with immunotherapy, and with atezolizumab (Tecentriq) and bevacizumab (Avastin) in treatment naïve patients.
Tvardi Therapeutics CEO Imran Alibhai said: “Enthusiasm for our HCC study continues to expand with recently presented clinical data demonstrating TTI-101 monotherapy has robust efficacy in heavily pretreated patients with HCC, published preclinical work highlighting TTI-101’s synergy with immunotherapy, and the FDA’s Fast-Track Designation for TTI-101 in HCC.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This is the second of three Phase II trials Tvardi has initiated to address diseases driven by STAT3.”
Tvardi is also evaluating TTI-101 in patients with idiopathic pulmonary fibrosis and metastatic breast cancer in Phase II clinical programmes.
TTI-101 is an orally delivered, small molecule, direct inhibitor of STAT3, a key regulatory protein responsible for the pathogenesis of HCC.
Patient enrolment in a TTI-101 Phase I trial has been completed. TTI-101 was well-tolerated as a monotherapy and showed multiple durable radiographic objective responses.
